NAYA Biosciences Files S-1/A Amendment
Ticker: IVF · Form: S-1/A · Filed: Jan 8, 2025 · CIK: 1417926
Sentiment: neutral
Topics: sec-filing, s-1a, company-update
TL;DR
NAYA Biosciences (formerly INVO Bioscience) filed an S-1/A. Watch for updates on their securities.
AI Summary
NAYA Biosciences, Inc. filed an S-1/A amendment on January 8, 2025, for its registration statement. The company, formerly known as INVO Bioscience, Inc., is incorporated in Nevada and operates in the surgical and medical instruments sector. Its principal executive offices are located in Sarasota, Florida.
Why It Matters
This filing indicates NAYA Biosciences is actively pursuing regulatory steps related to its securities, which could impact its stock and future fundraising activities.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to significant corporate actions like stock offerings or changes, which carry inherent market risks.
Key Numbers
- 3841 — SIC Code (Surgical & Medical Instruments & Apparatus industry)
- 20-4036208 — EIN (IRS Employer Identification Number)
Key Players & Entities
- NAYA Biosciences, Inc. (company) — Registrant
- January 8, 2025 (date) — Filing Date
- 333-283872 (registration_number) — SEC File Number
- INVO Bioscience, Inc. (company) — Former Company Name
- Steve Shum (person) — Chief Executive Officer
- Daniel Teper (person) — President
- Sarasota, Florida (location) — Principal Executive Offices
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a Form S-1 registration statement, indicating updates or changes to the company's initial filing regarding its securities.
When was this amendment filed?
The amendment was filed with the SEC on January 8, 2025.
What was NAYA Biosciences, Inc. previously known as?
NAYA Biosciences, Inc. was formerly known as INVO Bioscience, Inc.
Where are NAYA Biosciences, Inc.'s principal executive offices located?
The company's principal executive offices are located at 5582 Broadcast Court, Sarasota, Florida, 34240.
What industry does NAYA Biosciences, Inc. operate in?
NAYA Biosciences, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, with a SIC code of 3841.
Filing Stats: 4,370 words · 17 min read · ~15 pages · Grade level 15.6 · Accepted 2025-01-08 17:10:59
Key Financial Figures
- $0.0001 — of one share of common stock, par value $0.0001 per share (the “Common Stock&rdqu
- $0.87 — at an assumed public offering price of $0.87 per Unit. The warrants are exercisable
- $0 — includes a share of Common Stock, minus $0.0001, and the exercise price of the Pre
- $13,000,000 — ties Offered by us Up to a maximum of $13,000,000 of units (the “Units”), eac
Filing Documents
- forms-1a.htm (S-1/A) — 1966KB
- ex1-1.htm (EX-1.1) — 137KB
- ex4-29.htm (EX-4.29) — 141KB
- ex107.htm (EX-FILING FEES) — 21KB
- forms1_001.jpg (GRAPHIC) — 26KB
- forms1_002.jpg (GRAPHIC) — 32KB
- forms1_003.jpg (GRAPHIC) — 205KB
- forms1_004.jpg (GRAPHIC) — 13KB
- forms1_005.jpg (GRAPHIC) — 163KB
- forms1_006.jpg (GRAPHIC) — 306KB
- forms1_007.jpg (GRAPHIC) — 200KB
- 0001493152-25-001437.txt ( ) — 3570KB
BUSINESS
BUSINESS DESCRIPTION 68 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 81
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 103
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 111 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 112
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 113 PLAN OF DISTRIBUTION 118 LEGAL MATTERS 125 EXPERTS 125 WHERE YOU CAN FIND MORE INFORMATION 125 INCORPORATION OF DOCUMENTS BY REFERENCE 126 PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus. This summary does not contain all of the information that you should consider before investing in our Common Stock. You should carefully read this entire prospectus, and our other filings with the SEC, including the following sections, which are either included herein and/or incorporated by reference herein, “Risk Factors”, “Special Note Regarding Forward-Looking Statements”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements incorporated by reference herein, before making a decision about whether to invest in our securities . In this prospectus, unless context requires otherwise, references to “we,” “us,” “our,” “NAYA” or “the Company” refer to NAYA Biosciences, Inc. and its subsidiaries. THE COMPANY NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility. The Company utilizes a hub and spoke model that harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets as well as optimized return on investment by combining the upside of innovative clinical-stage therapeutics with scalable, profitable commercial revenues. The hub-and-spoke structure uses a centralized portfolio management team (the parent company or “Hub”) that owns and controls a set of subsidiaries (“Spokes”). The subsidiaries remain focused on their as